First patient dosed in Estrella’s STARLIGHT-1 Phase I/II trial

Phase 1EB103Positive

AI Analysis

Summary

Estrella Immunopharma has dosed the first patient in the dose-expansion segment of its STARLIGHT-1 Phase I/II trial evaluating EB103 for relapsed/refractory B-cell non-Hodgkin lymphoma.

Clinical Trial Data

Phase

Phase I/II

Importance:4/10

Sentiment:

0.30

clinical trialoncologyfirst patient doseddose expansion

Related Companies

$ESLAW

Read the original article

Published by Clinical Trials Arena on July 27, 2026 9:01 AM

Read Original